Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion ...

Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch –– Launched Niktimvo™ (axatilimab-csfr) in the U.S.

In The Lancet Hematology, Jorge E Cortes and colleagues1 report a phase 1/2 study on vodobatinib in patients with resistance ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...